Filing Details
- Accession Number:
- 0001140361-15-015897
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-04-20 19:18:25
- Reporting Period:
- 2015-04-17
- Filing Date:
- 2015-04-20
- Accepted Time:
- 2015-04-20 19:18:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1302573 | Oncomed Pharmaceuticals Inc | OMED | Pharmaceutical Preparations (2834) | 383572512 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1553353 | Austin Gurney | C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-04-17 | 3,850 | $25.47 | 67,569 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-04-17 | 150 | $26.52 | 67,419 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 16, 2014.
- This transaction was executed in multiple trades in prices ranging from $25.22 to $26.02, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
- This transaction was executed in multiple trades in prices ranging from $26.39 to $26.77, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.